Factor Xa inhibitors significantly reduced strokes and systemic embolic events compared to warfarin in patients with atrial fibrillation.
Do Factor Xa inhibitors reduce cerebral or systemic embolism compared to vitamin K antagonists in patients with atrial fibrillation?
Factor Xa inhibitors effectively reduce strokes and systemic embolic events compared to warfarin in patients with atrial fibrillation, with a favorable safety profile regarding intracranial hemorrhage.
Factor Xa inhibitors significantly reduced the number of strokes and systemic embolic events compared with warfarin in patients with AF. Factor Xa inhibitors also seem to reduce the number of major bleedings and ICHs compared with warfarin, though the evidence for a reduction of major bleedings is somewhat less robust. There is currently no conclusive evidence to determine which factor Xa inhibitor is more effective and safer for long-term anticoagulant treatment of patients with AF as head-to-head studies of the different factor Xa inhibitors have not yet been performed.
Slot et al. (2013) studied this question. Factor Xa inhibitors significantly reduced strokes and systemic embolic events compared to warfarin in patients with atrial fibrillation.